These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 22956867

  • 21. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G.
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [Abstract] [Full Text] [Related]

  • 22. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, Romero-Otero J, Martinez-Salamanca JI, Jones TH, Debruyne FMJ, Kurth KH, Hackett GI, Quinton R, Stroberg P, Reisman Y, Pescatori ES, Morales A, Bassas L, Cruz N, Cunningham GR, Wheaton OA, RHYME Investigators.
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [Abstract] [Full Text] [Related]

  • 23. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM, Paul RG, Yarndley T, Kamp J, Elston MS, Conaglen JV.
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [Abstract] [Full Text] [Related]

  • 24. Review of Testim gel.
    McNicholas T, Ong T.
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [Abstract] [Full Text] [Related]

  • 25. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
    McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA.
    BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
    [Abstract] [Full Text] [Related]

  • 26. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L, Lazarou S, Morgentaler A.
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [Abstract] [Full Text] [Related]

  • 27. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
    Liao CH, Wu YN, Lin FY, Tsai WK, Liu SP, Chiang HS.
    Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
    [Abstract] [Full Text] [Related]

  • 28. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA, Berhanu D, François N, Masson P, Zargaroff S, Cashy J, McVary KT.
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [Abstract] [Full Text] [Related]

  • 29. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS.
    JAMA; 2006 Nov 15; 296(19):2351-61. PubMed ID: 17105798
    [Abstract] [Full Text] [Related]

  • 30. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
    Lundy SD, Parekh NV, Shoskes DA.
    J Sex Med; 2020 Jul 15; 17(7):1297-1303. PubMed ID: 32307242
    [Abstract] [Full Text] [Related]

  • 31. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
    Cunningham GR, Ellenberg SS, Bhasin S, Matsumoto AM, Parsons JK, Preston P, Cauley JA, Gill TM, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Pahor M, Crandall JP, Molitch ME, Cifelli D, Basaria S, Diem SJ, Stephens-Shields AJ, Hou X, Snyder PJ.
    J Clin Endocrinol Metab; 2019 Dec 01; 104(12):6238-6246. PubMed ID: 31504596
    [Abstract] [Full Text] [Related]

  • 32. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
    Schoenfeld MJ, Shortridge E, Cui Z, Muram D.
    J Sex Med; 2013 May 01; 10(5):1401-9. PubMed ID: 23464534
    [Abstract] [Full Text] [Related]

  • 33. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
    Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ.
    BJU Int; 2010 May 01; 105(10):1397-401. PubMed ID: 19912179
    [Abstract] [Full Text] [Related]

  • 34. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
    Li H, Mitchell L, Zhang X, Heiselman D, Motsko S.
    J Sex Med; 2017 Nov 01; 14(11):1307-1317. PubMed ID: 29110802
    [Abstract] [Full Text] [Related]

  • 35. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A, Almehmadi Y, Saad F, Doros G, Gooren L.
    Clin Endocrinol (Oxf); 2016 Jan 01; 84(1):107-14. PubMed ID: 26331709
    [Abstract] [Full Text] [Related]

  • 36. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
    Choi EJ, Xu P, Barham D, El-Khatib FM, Yafi FA, Kavoussi PK.
    J Urol; 2022 Mar 01; 207(3):677-683. PubMed ID: 34694927
    [Abstract] [Full Text] [Related]

  • 37. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H, Seltzer J, Talbert RL.
    Am J Health Syst Pharm; 2015 Apr 01; 72(7):536-41. PubMed ID: 25788507
    [Abstract] [Full Text] [Related]

  • 38. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M.
    Int J Impot Res; 2013 Jan 01; 25(1):24-8. PubMed ID: 22971614
    [Abstract] [Full Text] [Related]

  • 39. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
    Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J.
    Endocr Pract; 2017 May 01; 23(5):557-565. PubMed ID: 28225313
    [Abstract] [Full Text] [Related]

  • 40. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.
    Clin Endocrinol (Oxf); 1997 Dec 01; 47(6):727-37. PubMed ID: 9497881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.